Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
Transl Cancer Res
.
2019 Dec;8(8):E11-E14.
doi: 10.21037/tcr.2019.12.57.
Authors
Teppei Yamaguchi
1
,
Toyoaki Hida
1
Affiliation
1
Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
PMID:
35117056
PMCID:
PMC8798102
DOI:
10.21037/tcr.2019.12.57
No abstract available
Publication types
Editorial
Comment